6th CDDD Meeting computationally driven drug discovery
March 28-29 Rome, Italy 6th CDDD Meeting computationally driven drug discovery
3rd World Conference on Cancer biology and immunology
March 11-12 Milan, Italy 3rd World Conference on Cancer biology and immunology
Pre-clinical mouse models and breast cancer organoids reveal clues to therapeutic resistance and disease progression
November 20, 2018 (1:30 PM) Pre-clinical mouse models and breast cancer organoids reveal clues to therapeutic resistance and disease progression Kristina Havas Metabolism, Epigenetics and Breast Cancer, FIRC Institute for Molecular Oncology, IFOM Milan
The physic of collective cancer migration
November 13, 2018 (1:30 PM) The physic of collective cancer migration Giorgio Scita Tumor Cell Migration Unit, IFOM Milano & Department of Oncology, University of Milan
Pathology Lab for Translational Medicine
October 10, 2018 (1:30 PM) Pathology Lab for Translational Medicine Giancarlo Pruneri Dip. Anatomia Patologica 2, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
Treatment options in high risk multiple myeloma
October 16, 2018 (1:30 PM) Treatment options in high risk multiple myeloma Paolo Corradini Dip. Oncologia Medica ed Ematologia, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
Targeting acute leukemia by lipid-antigen specific T cells restricted for CD1
April 6, 2018 (1:30 PM) Targeting acute leukemia by lipid-antigen specific T cells restricted for CD1 Giulia Casorati Experimental Immunology Unit, DIBIT, San Raffaele Scientific Institute Milan
Ruolo della terapia con PARP inibitori nel trattamento del tumore ovarico
February 21, 2018 (1:30 PM) Ruolo della terapia con PARP inibitori nel trattamento del tumore ovarico Domenica Lorusso Chirurgia Ginecologica Fondazione IRCCS Istituto Nazionale dei Tumori Milan
Global Medicinal Chemistry & GPCR Leaders Summit
27-28 novembre London, UK Global Medicinal Chemistry & GPCR Leaders Summit Oral presentation: The systematic use of highly profiled antitumor agents in probing the sensitivity contexts of cancer cells and assessing the validity of target combinations
European Molecular Biology Laboratory Conference
5-8 novembre Heidelberg, Germany European Molecular Biology Laboratory Conference